Neil O Carragher
Overview
Explore the profile of Neil O Carragher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishii Y, Orr J, El Mdawar M, de Pilger D, Pearce D, Lazarus K, et al.
J Cell Sci
. 2025 Mar;
PMID: 40065746
Regeneration of the airway epithelium restores barrier function and mucociliary clearance following lung injury and infection. The mechanisms regulating the proliferation and differentiation of tissue-resident airway basal stem cells remain...
2.
Shave S, Isaksson R, Pham N, Elliott R, Dawson J, Soudant J, et al.
ACS Omega
. 2025 Mar;
10(7):6794-6800.
PMID: 40028100
Analysis of observed protein sequences across all species within the UniProtKB/Swiss-Prot data set reveals CQWW as the shortest absent stretch of amino acids. While DNA can be found encoding the...
3.
Graham R, Zheng R, Wagner J, Unciti-Broceta A, Hay D, Forbes S, et al.
iScience
. 2025 Feb;
28(2):111871.
PMID: 39995868
We have developed a single-cell assay that combines Cell Painting-a morphological profiling assay-with trajectory inference analysis. We have applied this morphological trajectory inference to the bi-potent HepaRG liver progenitor cell...
4.
Ford C, Koludrovic D, Centeno P, Foth M, Tsonou E, Vlahov N, et al.
Cancer Res
. 2024 Dec;
85(4):808-824.
PMID: 39636745
Metastatic melanoma remains a major clinical challenge. Large-scale genomic sequencing of melanoma has identified bona fide activating mutations in RAC1, which are associated with resistance to BRAF-targeting therapies. Targeting the...
5.
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran P, Brice M, Sutherland E, Hoy A, Papachristoforou E, Jia L, et al.
Hepatol Commun
. 2024 Nov;
8(12).
PMID: 39585303
Background: The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH)-related fibrosis. INT-767, a potent FXR agonist, has shown promise in preclinical models. We aimed...
6.
Ayala-Aguilera C, Ge Y, Lorente-Macias A, Jones B, Adam C, Carragher N, et al.
RSC Med Chem
. 2024 Nov;
PMID: 39493221
Oesophageal cancer (OC) is one of the leading causes of cancer-related deaths worldwide. Due in part to its high heterogeneity, OC prognosis remains poor despite the introduction of targeted and...
7.
Loftus A, Romano M, Phuong A, McKinnel B, Muir M, Furqan M, et al.
Dev Cell
. 2024 Sep;
59(24):3197-3212.e7.
PMID: 39326421
Glioblastoma (GBM) is driven by malignant neural stem-like cells that display extensive heterogeneity and phenotypic plasticity, which drive tumor progression and therapeutic resistance. Here, we show that the extracellular matrix-cell...
8.
Pal S, Chataway J, Swingler R, Macleod M, Carragher N, Hardingham G, et al.
Lancet Neurol
. 2024 Sep;
23(11):1097-1107.
PMID: 39307154
Background: Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of...
9.
Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, et al.
J Biol Chem
. 2024 Aug;
300(9):107615.
PMID: 39089584
NXP900 is a selective and potent SRC family kinase (SFK) inhibitor, currently being dosed in a phase 1 clinical trial, that locks SRC in the "closed" conformation, thereby inhibiting both...
10.
Hollis R, Elliott R, Dawson J, Ilenkovan N, Matthews R, Stillie L, et al.
Gynecol Oncol
. 2024 Apr;
186:42-52.
PMID: 38582027
Background: Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening...